
Renal Denervation Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Description
Renal Denervation Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Renal Denervation Catheters Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Renal Denervation Catheters pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Renal denervation, also known as renal sympathetic denervation (RSD), is a minimally invasive, catheter-based endovascular procedure that utilizes radiofrequency energy or ultrasound energy to ablate nerves in the walls of the renal artery, causing a reduction in the nerve activity which ultimately reduces the blood pressure in patients with resistant hypertension.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Renal Denervation Catheters under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Renal Denervation Catheters and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Renal Denervation Catheters under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
104 Pages
- Renal Denervation Catheters Overview
- Renal Denervation Catheters - Pipeline Products by Stage of Development
- Renal Denervation Catheters - Pipeline Products by Segment
- Renal Denervation Catheters - Pipeline Products by Territory
- Renal Denervation Catheters - Pipeline Products by Regulatory Path
- Renal Denervation Catheters - Pipeline Products by Estimated Approval Date
- Renal Denervation Catheters - Ongoing Clinical Trials
- Renal Denervation Catheters Companies - Pipeline Products by Stage of Development
- Renal Denervation Catheters - Pipeline Products by Stage of Development
- Abbott Vascular Inc Company Overview
- Ablative Solutions Inc Company Overview
- Brattea Company Overview
- CryoMedix, LLC. Company Overview
- Handok-Kalos Medical Company Overview
- Johns Hopkins University Company Overview
- Kona Medical Inc Company Overview
- Lepu Medical Technology (Beijing) Co Ltd Company Overview
- Lifetech Scientific (Shenzhen) Co Ltd Company Overview
- Mayo Clinic Company Overview
- Medtronic Plc Company Overview
- MicroPort Scientific Corp Company Overview
- Northwind Medical Inc Company Overview
- Rainmed Medical Ltd Company Overview
- ReCor Medical Inc Company Overview
- Renal Dynamics, LLC Company Overview
- Renaly Ltd Company Overview
- Shanghai AngioCare Medical Technology Co Ltd Company Overview
- Shanghai Golden Leaf Medtech Co Ltd Company Overview
- SoniVie Ltd. Company Overview
- Sound Interventions, Inc. Company Overview
- St. Jude Medical LLC Company Overview
- Suzhou Xinmai Medical Equipment Co Ltd Company Overview
- Symple Surgical Inc Company Overview
- Tel Aviv University Company Overview
- Terumo Interventional Systems Company Overview
- University of Sydney Company Overview
- Venus Medtech Hangzhou Inc Company Overview
- Verve Medical, Inc. Company Overview
- Jun 04, 2024: Medtronic Announces Dr. Goran Petrovski to Join Diabetes Medical Affairs Team
- Jun 04, 2024: Medtronic Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024
- May 07, 2024: Medtronic's renal denervation system receives approval in China
- Apr 24, 2024: Medtronic Names Yarmela Pavlovic as Chief Regulatory Officer
- Apr 18, 2024: Recor Medical Announces First Cases of Paradise Ultrasound Renal Denervation Therapy in the United Arab Emirates
- Apr 11, 2024: Ablative Solutions' TARGET BP I Pivotal Trial Results Demonstrate Significant Reduction in 24-Hour Ambulatory Systolic Blood Pressure Compared to Sham, Using Alcohol-Mediated Renal Denervation
- Mar 14, 2024: Tampa General Hospital Employs New Ultrasound Therapy Designed to Treat Life-Threatening Hypertension
- Mar 12, 2024: Medtronic To Present At Barclays Global Healthcare Conference
- Feb 28, 2024: Boston Scientific Raises $2.2B to Support Purchase of California Medical Device Company
- Feb 23, 2024: Medical Tech Leader, Boston Scientific (BSX), Announces Notes Offering
- Feb 19, 2024: Boston Scientific Appoints Madan Krishnan to Lead India Subcontinent
- Feb 16, 2024: Jim Robo, Former Chairman and CEO of NextEra Energy, to Join Mayo Clinic Board of Trustees
- Feb 07, 2024: Terumo Announces Change of Executive Officers (PDF 232.27 KB)
- Feb 02, 2024: SoniVie completes enrolment in renal denervation study
- Jan 31, 2024: Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
- Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
- Dec 22, 2023: Medtronic Launches Symplicity Blood Pressure Procedure - A new Horizon in Managing Patients with Hypertension in India
- Dec 19, 2023: Ablative Solutions Announces Primary Endpoint Met in the TARGET BP I Pivotal Trial of the Peregrine System Kit for Patients with Uncontrolled Hypertension
- Dec 13, 2023: MarinHealth Interventional Cardiologists Are First on the West Coast to Perform Symplicity Renal Denervation Procedure Outside of a Clinical Trial
- Dec 09, 2023: Baylor Scott & White Heart and Vascular Hospital - Dallas Deploys FDA-Approved Hypertension Treatment
- Nov 28, 2023: Medtronic Obtains Pre-Market Approval (PMA) For Symplicity Spyral Renal Denervation System
- Nov 28, 2023: First Patient Treated With Medtronic Symplicity Spyral Renal Denervation System at Piedmont
- Nov 17, 2023: Medtronic Announces FDA Approval of Minimally Invasive Device to Treat Hypertension
- Nov 16, 2023: ReCor Medical Obtains Pre-Market Approval (PMA) for Paradise Ultrasound Renal Denervation System
- Nov 13, 2023: Recor Medical introduces Paradise uRDN system in US
- Nov 08, 2023: Recor Medical receives FDA approval for hypertension treatment system
- Oct 27, 2023: Positive six-month follow-up results for Recor's renal denervation system
- Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023
- Oct 20, 2023: Recor Medical to Present Latest Clinical Data on Paradise Ultrasound Renal Denervation at TCT Annual Meeting
- Oct 04, 2023: Medtronic Names Paolo Di Vincenzo President of the Neuromodulation Business
- Aug 26, 2023: Medtronic Q2 2024 Earnings Estimates Increased by William Blair
- Aug 23, 2023: Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel Vote for the Symplicity Spyral Renal Denervation System
- Aug 22, 2023: Otsuka Medical Devices and Recor Medical Announce Positive Vote from U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on the Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension
- Aug 17, 2023: Mayo Clinic Reports Strong Finances for 2023 So Far with Q2 Revenue of $4.47 billion
- Aug 11, 2023: Kristin Peck, CEO of Zoetis, to join Mayo Clinic Board of Trustees
- Aug 08, 2023: Medtronic to Announce Financial Results for its First Quarter of Fiscal Year 2024
- Jul 19, 2023: Boston Scientific lays off 52 workers as it closes another Silicon Valley facility
- Jul 14, 2023: ReCor Responds to European Society of Hypertension's (ESH) Updated Guidelines for Management of Arterial Hypertension
- Jul 11, 2023: Verve Medical Announces FDA Approval of IDE for Pivotal Trial of RPD Renal Pelvic Denervation System for Treatment of Uncontrolled Hypertension
- Jul 03, 2023: Medtronic Statement on ESH Guidelines for Hypertension and Renal Denervation
- Jun 30, 2023: Bioheart Announces Clinical Result for Iberis-HTN at CIT 2023
- Jun 27, 2023: Kalos Medical Receives Korean MFDS Innovative Medical Device Designation for DENEX Hypertension Treatment System
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.